Extended ischemic times during ex vivo lung perfusion is not associated with increased mortality

Doug A. Gouchoe,Divyaam Satija,Ervin Y. Cui,Ahmed Aly,Matthew C. Henn,Kukbin Choi,David Nunley,Nahush A. Mokadam,Asvin M. Ganapathi,Bryan A. Whitson
DOI: https://doi.org/10.1111/aor.14820
2024-08-22
Artificial Organs
Abstract:If EVLP technology is available, under certain circumstances, surgeons should not be dissuaded from using an allograft with extended ischemic time. Background The purpose of this study was to identify the association of increasing ischemic times in recipients who receive lungs evaluated by ex vivo lung perfusion (EVLP) and their association with outcomes following lung transplantation. Methods Lung transplant recipients who received an allograft evaluated by EVLP were identified from the United Network for Organ Sharing (UNOS) Database from 2016–2023. Recipients were stratified into three groups based on total ischemic time (TOT): short TOT (STOT, 0 to to <14 h), and long TOT (LTOT, +14 h). The groups were assessed with comparative statistics and Kaplan–Meier methods. A Cox regression was created to determine the association of ischemic time in EVLP donors and long‐term mortality. Results Recipients in the LTOT group had significantly longer length of stay and post‐operative extracorporeal membrane use at 72 h (p 0.05 for both). On multivariable analysis, ischemic time was not associated with increased mortality whereas increasing recipient age, preoperative ECMO use and donation after circulatory death donors were (p
engineering, biomedical,transplantation
What problem does this paper attempt to address?